Comprehensive Analysis of the Prognostic Value and Biological Function of TDG in Hepatocellular Carcinoma

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2023 May 24

PMID 37224078

Authors

Guoliang Wang

Yinwen Zhou

Bin Yi

Yanli Long

Bo Ma

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Epigenetics plays an important role in the malignant progression of tumors, in which DNA methylation can alter genetic performance without altering the DNA sequence. As a key regulator demethylation, thymine-DNA glycosylase (TDG) has been reported to participate in malignant progression of multiple tumors. In this study, we demonstrate that TDG is highly expressed in hepatocellular carcinoma (HCC) and its high expression is closely related to the poor prognosis of patients. Decreasing TDG expression can significantly inhibit the malignant biological behavior of HCC cells. ABL proto-oncogene 1(ABL1) was identified as a downstream gene regulated by TDG demethylation. In addition, TDG can affect the Hippo signaling pathway through ABL1 to regulate HCC cell proliferation, apoptosis, invasion and migration. Overall, our study demonstrated that TDG reduces DNA methylation of ABL1, increases ABL1 protein expression, and affects the Hippo signaling pathway to regulate the malignant progression of HCC.

Citing Articles

Association of APC Expression with Its Promoter Methylation Status and the Prognosis of Hepatocellular Carcinoma.

Xing W, Li Y, Chen J, Hu Q, Liu P, Ge X Asian Pac J Cancer Prev. 2023; 24(11):3851-3857.

PMID: 38019243 PMC: 10772746. DOI: 10.31557/APJCP.2023.24.11.3851.

References

Maleki Behzad M, Shahrabi S, Jaseb K, Bertacchini J, Ketabchi N, Saki N . Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response. Biochem Genet. 2018; 56(3):149-175. DOI: 10.1007/s10528-018-9841-1. View

Kang G, Park J, Kim H, Kim E, Kim B, Byun H . PRR16/Largen Induces Epithelial-Mesenchymal Transition through the Interaction with ABI2 Leading to the Activation of ABL1 Kinase. Biomol Ther (Seoul). 2022; 30(4):340-347. PMC: 9252882. DOI: 10.4062/biomolther.2022.066. View

Wu H, Qiu J, Wu Z, He T, Zhou C, Lv Q . MiR-27a-3p binds to TET1 mediated DNA demethylation of ADCY6 regulates breast cancer progression epithelial-mesenchymal transition. Front Oncol. 2022; 12:957511. PMC: 9377375. DOI: 10.3389/fonc.2022.957511. View

Kohli R, Zhang Y . TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013; 502(7472):472-9. PMC: 4046508. DOI: 10.1038/nature12750. View

Couri T, Pillai A . Goals and targets for personalized therapy for HCC. Hepatol Int. 2019; 13(2):125-137. DOI: 10.1007/s12072-018-9919-1. View

Jiang L, Yang Y, Fu L, Xu W, Liu D, Liang Q . CLDN3 inhibits cancer aggressiveness via Wnt-EMT signaling and is a potential prognostic biomarker for hepatocellular carcinoma. Oncotarget. 2014; 5(17):7663-76. PMC: 4202152. DOI: 10.18632/oncotarget.2288. View

Liu F, Kong X, Lv L, Gao J . TGF-β1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. Cancer Lett. 2015; 359(2):288-98. DOI: 10.1016/j.canlet.2015.01.030. View

Yoon J, Iwai S, OConnor T, Pfeifer G . Human thymine DNA glycosylase (TDG) and methyl-CpG-binding protein 4 (MBD4) excise thymine glycol (Tg) from a Tg:G mispair. Nucleic Acids Res. 2003; 31(18):5399-404. PMC: 203315. DOI: 10.1093/nar/gkg730. View

Miao J, Zhao C, Tang K, Xiong X, Wu F, Xue W . TDG suppresses the migration and invasion of human colon cancer cells via the DNMT3A/TIMP2 axis. Int J Biol Sci. 2022; 18(6):2527-2539. PMC: 8990457. DOI: 10.7150/ijbs.69266. View

10.

Cheng T, Xu M, Qin B, Wu J, Tu Y, Kang L . lncRNA H19 contributes to oxidative damage repair in the early age-related cataract by regulating miR-29a/TDG axis. J Cell Mol Med. 2019; 23(9):6131-6139. PMC: 6714223. DOI: 10.1111/jcmm.14489. View

11.

Ye X, Weinberg R . Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends Cell Biol. 2015; 25(11):675-686. PMC: 4628843. DOI: 10.1016/j.tcb.2015.07.012. View

12.

Massimino M, Stella S, Tirro E, Pennisi M, Vitale S, Puma A . ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives. Anticancer Res. 2020; 40(5):2457-2465. DOI: 10.21873/anticanres.14215. View

13.

Yan J, Lai C, Jhu J, Gongol B, Marin T, Lin S . Insulin and Metformin Control Cell Proliferation by Regulating TDG-Mediated DNA Demethylation in Liver and Breast Cancer Cells. Mol Ther Oncolytics. 2020; 18:282-294. PMC: 7378318. DOI: 10.1016/j.omto.2020.06.010. View

14.

Zheng Y, Pan D . The Hippo Signaling Pathway in Development and Disease. Dev Cell. 2019; 50(3):264-282. PMC: 6748048. DOI: 10.1016/j.devcel.2019.06.003. View

15.

Onabote O, Hassan H, Isovic M, Torchia J . The Role of Thymine DNA Glycosylase in Transcription, Active DNA Demethylation, and Cancer. Cancers (Basel). 2022; 14(3). PMC: 8833622. DOI: 10.3390/cancers14030765. View

16.

Bochtler M, Kolano A, Xu G . DNA demethylation pathways: Additional players and regulators. Bioessays. 2016; 39(1):1-13. DOI: 10.1002/bies.201600178. View

17.

Edwards J, Yarychkivska O, Boulard M, Bestor T . DNA methylation and DNA methyltransferases. Epigenetics Chromatin. 2017; 10:23. PMC: 5422929. DOI: 10.1186/s13072-017-0130-8. View

18.

Dey A, Varelas X, Guan K . Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020; 19(7):480-494. PMC: 7880238. DOI: 10.1038/s41573-020-0070-z. View

19.

Chiaretti S, Messina M, Foa R . BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?. Cancer. 2018; 125(2):194-204. DOI: 10.1002/cncr.31848. View

20.

Pastushenko I, Blanpain C . EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2018; 29(3):212-226. DOI: 10.1016/j.tcb.2018.12.001. View